Healthcare
CVS Group PLC(CVSGF)
Live Price
Offline$16.55
+0.00% today
1Y Change
-4.89%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $800.00M
- Revenue Growth
- +42.8%
- EPS Growth
- +327.3%
- Dividend Yield
- 0.7%
Coverage: 254 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CVS Group PLC (CVSGF) is a Healthcare stock with a market cap of $800.00M and listed on OTC. The stock last traded around $16.55 and down 4.9% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +42.8%, EPS growth of +327.3%, a dividend yield of 0.7%. What stands out right now is revenue +42.8%, EPS +327.3%, free cash flow +209.6% with operating margin 10.4% and ROIC 6.2%. The dividend is present but secondary, with a yield around 0.7%. Valuation already assumes a fairly strong business story at P/E 51.3 and price/sales 1.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines CVSGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+42.8% vs +7.6% peer median
Operating Margin
Below sector median
+10.4% vs +19.4% peer median
P/E
Above sector median
51.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 26, 2026 with an EPS surprise of -7.3% and a revenue surprise of -1.5%.
The operating story is still moving forward
Revenue is running at +42.8% and EPS at +327.3%, with operating margin around 10.4%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 24, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 26, 2026 | -7.3% | +0.0% | +1.7% | +1.7% |
2025 Oct 7, 2025 | -47.8% | +0.0% | +0.0% | +0.0% |
2025 Feb 26, 2025 | -61.9% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
CVSGF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CVSGF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CVSGF Max Drawdown
-17.89%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CVSGF and SPY.
Company Overview
CVS Group PLC
OTC
CVS Group plc is a leading integrated veterinary services provider primarily operating in the United Kingdom and Australia. Established in 1999, the company delivers comprehensive animal care through four main divisions: veterinary practices, diagnostic laboratories, pet crematoria, and an online retail business focused on pet pharmacy via Animed Direct. Its veterinary practices form the core revenue generator, offering first-opinion care, out-of-hours services, specialist referrals, and preventative health programs like the Healthy Pet Club. Supported by in-house laboratories for rapid diagnostics and crematoria services, CVS Group plc emphasizes clinical excellence, continuous professional development, and a robust quality improvement framework led by over 500 clinical advocates. With approximately 8,900 employees, including 2,300 veterinary surgeons and 3,200 nurses across more than 500 practices and 40 dedicated out-of-hours sites, the company fosters an inclusive workplace prioritizing colleague wellbeing, career progression, and innovation. Listed on the London Stock Exchange, CVS Group plc plays a pivotal role in consolidating and modernizing the veterinary sector, enhancing animal healthcare standards through technology, research funding, and extensive support networks.
- Leadership
- Mr. Richard William Mark Fairman F.C.A.
- Employees
- 9.0k
- Street Address
- CVS House, Owen Road
- Mailing
- Diss, IP22 4ER
- Region
- Diss, United Kingdom
- Last Updated
- May 9, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 51.3
- EV/EBITDA
- 9.3
- Price/Sales
- 1.2
- Price/Book
- 2.8
Growth
- Revenue
- +42.8%
- EPS
- +327.3%
- Free Cash Flow
- +209.6%
Profitability
- Gross Margin
- 39.0%
- Operating Margin
- 10.4%
- Net Margin
- 2.3%
- ROE
- 5.3%
- ROIC
- 6.2%
Balance Sheet
- Debt/Equity
- 1.22
- Current Ratio
- 1.07
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.